Clinical trial

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

NCT03333343

StatusACTIVE_NOT_RECRUITING

Study typeINTERVENTIONAL

Start date2018-01-29

PhasePHASE1

Study timeline

Study start (actual)2018-01-29Date precision: day

Registry last updated2026-01-16

Observed by CureCurrent2026-10-07

Recorded dates are source observations, not predictions. Missing milestones are not estimated.

Conditions

EGFR-mutant Non-small Cell Lung Cancerunresolved

Interventions

EGF816DRUG

trametinibDRUG · verified · RxNorm: trametinib

ribociclibDRUG · verified · RxNorm: ribociclib

LXH254DRUG

INC280DRUG

gefitinibDRUG · verified · RxNorm: gefitinib

Sponsors & collaborators

Novartis Pharmaceuticalslead sponsor

Mapped research locations

SingaporeSingapore2 TorontoOntario, Canada1 TaipeiTaiwan1 EssenGermany1 TainanTaiwan1 Hong KongHong Kong1

Registry source

Open the source record to verify current eligibility, contacts, locations and registry updates.

Open NCT03333343 on ClinicalTrials.gov ↗

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.